Synchronous bilateral urothelial cancer in a kidney recipient

International Journal of Urology

Volumn 18, Issue 12, 2011, Pages 847-850

  Nakazawa, Ryuto ^a   Miyano, Satetsu ^a   Sasaki, Hideo ^a   Kudo, Hiroya ^a   Kimura, Kenjiro ^a   Chikaraishi, Tatsuya ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Asymptomatic hematuria; Gemcitabine cisplatin chemotherapy; Kidney transplantation; Reduced immunosuppression; Urothelial cancer

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CISPLATIN; CREATININE; CYCLOSPORIN; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE;

ADULT; ADVANCED CANCER; ALBUMINURIA; ALPORT SYNDROME; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; CREATININE CLEARANCE; DRUG DOSE REDUCTION; ERYTHROCYTE TRANSFUSION; FOLLOW UP; GRAFT RECIPIENT; GRANULOCYTOPENIA; HEMATURIA; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; NEPHROURETERECTOMY; OPERATION DURATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL GRAFT DYSFUNCTION; RETROGRADE PYELOGRAPHY; TRANSITIONAL CELL CARCINOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; HUMANS; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; MALE; NEOPLASMS, MULTIPLE PRIMARY; URETERAL NEOPLASMS; UROTHELIUM;

EID: 83055176502     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02854.x     Document Type: Article

References (10)

1. Imanishi M, Kunikata S, Akiyama T, Kurita T. Study on the seven cases of malignant tumor after renal transplantation in our institution and statistic data of malignant tumor after renal transplantation in Japan. Jpn J. Transplant. 1996; 31: 100-7.
2. Hoshida Y, Tsukuma H, Yasunaga Y etal. Cancer risk after renal transplantation in Japan. Int. J. Cancer 1997; 71: 517-20.
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Terasaki P, Cecka JM (eds). Clinical Transplants. UCLA Tissue Typing Laboratory, Los Angeles, CA, 1994; 99-109.
4. Sheil A. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant. Proc. 1993; 25: 1383-4.
5. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am. J. Transplant. 2004; 4: 905-13.
6. Bustami RT, Ojo AO, Wolfe RA etal. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am. J. Transplant. 2004; 4: 87-93.
7. Previte SR, Murata GT, Olsson CA, Schmitt GW, Nabseth DC, Cho SI. Hematuria in renal transplant recipients. Ann. Surg. 1978; 187: 219-22.
8. Liao CH, Chueh SCJ, Lai MK, Chen J. Transitional cell carcinoma in renal transplant recipients. Transplant. Proc. 2004; 36: 2152-53.
9. von der Maase H, Hansen SW, Roberts JT etal. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000; 18: 3068-77.
10. Geissler EK, Schlitt H. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int. 2010; 78: 1075-9.